Tag: CDE

Categories
CDE Diabetes

Study Guide: Diabetes and Driving (Chapter 21)

1. Overview & Rationale

Diabetes can affect driving safety primarily through the risk of hypoglycemia (which impairs cognitive and motor function) and long-term complications (like retinopathy or neuropathy) that affect sensory/motor abilities.

  • Individual Assessment: Fitness to drive must be assessed on an individual basis.

  • The Major Risk: Severe hypoglycemia is the most significant predictor of driving accidents among people with diabetes.

  • Shared Responsibility: Safety is a shared responsibility between the person with diabetes, the healthcare team, and the licensing bodies.

2. Medical Assessment for Fitness to Drive

The frequency and stringency of medical assessments depend on the type of license held.

FeaturePrivate
Drivers 		Commercial
Drivers
Assessment FrequencyAt least every 2 years (or more often if clinically indicated).At time of application and then as per provincial requirements.
Hypo RiskLower standard than commercial.Stricter standard.
ExclusionMay be restricted if uncontrolled severe hypoglycemia or unawareness.Often disqualified if they have severe hypoglycemia or hypoglycemia unawareness.

Key Assessment Components:

  1. Hypoglycemia History: Frequency, severity, and awareness of hypoglycemia in the past 12 months.

  2. Complications:

    • Vision: Retinopathy, cataracts, visual acuity, field of vision.

    • Neuropathy: Sensory or motor loss in limbs affecting pedal use.

    • Cognition: Impairment affecting judgment or reaction time.

3. High-Risk Drivers

Healthcare providers must identify individuals at increased risk of accidents.

Red Flags for Driving Safety:

  • Severe Hypoglycemia: Any episode of severe hypoglycemia (requiring assistance) in the past 12 months.

  • Hypoglycemia Unawareness: Inability to detect dropping glucose levels.

  • Recent instability: Unexplained or uncontrolled fluctuation in blood glucose.

  • Non-adherence: Failure to follow “safe driving” protocols (e.g., testing before driving).

4. Patient Education: The "Safe Driving" Protocol

Educating patients on how to drive safely is a mandatory CDE competency.

Before Driving:

  • Measure: Check blood glucose (BG) immediately before driving.

  • Safe Threshold:

    • If BG 4.0 mmol/L: Safe to drive (though some experts suggest 5.0 mmol/L is a safer buffer).

    • If BG < 4.0 mmol/L: DO NOT DRIVE. Treat with 15g carbs, retest in 15 mins.

    • Note: Even if BG is 4.0–5.0 mmol/L, consider a snack to prevent a drop during the drive.

While Driving (Long Trips):

  • Check BG every 4 hours during continuous driving.

  • Carry rapid-acting carbohydrates within easy reach (console, passenger seat).

If Hypoglycemia Occurs While Driving:

  1. Stop: Pull over safely immediately.

  2. Turn Off: Turn off the engine and remove keys (to legally establish you are not “driving”).

  3. Treat: Ingest 15g fast-acting carbohydrate.

  4. Wait: Wait 40 minutes after BG has returned to normal (> 4.0 mmol/L) before driving again.

    • Why 40 minutes? It takes time for cognitive recovery (brain function) to fully return even after the blood sugar is normal.

5. Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section.

  1. Individual Assessment: Fitness to drive should be assessed individually for all people with diabetes [Grade D, Consensus].

  2. Mandatory Exams:

    • Private Drivers: Medical examination at least every 2 years [Grade D, Consensus].

    • Commercial Drivers: Examination at application and as per provincial rules [Grade D, Consensus].

  3. Risk Factors: Assessing fitness to drive should include reviewing severe hypoglycemia episodes, hypoglycemia unawareness, and complications (retinopathy, neuropathy, nephropathy, CVD) [Grade D, Consensus].

  4. Patient Education: People with diabetes treated with insulin/secretagogues should be instructed to:

    • Keep fast-acting carbs within reach [Grade D, Consensus].

    • Measure BG before driving and every 4 hours during long drives [Grade D, Consensus].

    • Stop immediately if hypo occurs, treat, and wait 40 minutes after recovery before driving [Grade B, Level 2].

Reference:

Houlden RL, Berard L, Lakoff JM, Woo V, Yale JF. Diabetes and Driving. Canadian Journal of Diabetes. 2018;42:S150-S153. doi:10.1016/j.jcjd.2017.10.018
Categories
CDE Diabetes

Flashcards: Diabetes and Transplantation (Chapter 20)

Transplantation represents a life-changing therapeutic option for select patients with diabetes, particularly those with end-stage renal disease (ESRD). These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding the specific benefits of kidney, pancreas, and islet transplantation, as well as the management of post-transplant complications.

Key Topics Covered:

  • Kidney Transplantation: Understanding the evidence that kidney transplantation provides superior long-term survival compared to dialysis for patients with diabetes and ESRD.

  • Simultaneous Pancreas-Kidney (SPK): Identifying SPK as a strategy to prolong insulin independence and improve kidney graft survival in Type 1 diabetes.

  • Islet Transplantation: Recognizing the role of islet allotransplantation in preventing severe hypoglycemia, despite the trade-off of long-term immunosuppression.

  • Islet Autotransplantation: Recalling the indication for this procedure in patients undergoing total pancreatectomy for benign disease to prevent labile diabetes.

  • Post-Transplant Diabetes (PTDM): Managing the risks associated with PTDM, including its impact on graft loss, cardiovascular disease, and mortality.

Categories
CDE Diabetes

Practice Exam: Diabetes and Transplantation (Chapter 20)

For people with diabetes and end-stage renal disease (ESRD), transplantation offers the potential for significantly improved survival and quality of life compared to dialysis. However, the procedure introduces new challenges, including the management of post-transplant diabetes mellitus (PTDM) and the complex side effects of immunosuppressive therapy.

This practice exam tests your understanding of the indications for various transplant modalities (kidney, pancreas, islet) and the evidence-based strategies for managing glycemic control in the transplant recipient.

Key Concepts Covered in This Exam:

  • Renal Replacement: Understanding the evidence that kidney transplantation improves long-term outcomes compared to dialysis for individuals with diabetes and ESRD.

  • Transplant Types: Differentiating between Simultaneous Pancreas-Kidney (SPK) transplantation, which can prolong insulin independence, and islet allotransplantation, which focuses on preventing severe hypoglycemia.

  • Islet Autotransplantation: Recognizing the role of this procedure in preventing labile diabetes for patients undergoing total pancreatectomy for benign disease.

  • Post-Transplant Diabetes (PTDM): Identifying PTDM as a common complication after solid organ transplantation that increases the risk of graft loss, cardiovascular disease, and mortality.

  • Management Considerations: Balancing glycemic targets with the metabolic impact of antirejection medications.

1. What is the reported 5-year insulin independence rate with current islet transplantation protocols?

2. A 48-year-old woman is 6 weeks post-kidney transplant and is taking prednisone as part of her immunosuppression regimen. You need to screen for hyperglycemia. What is the most sensitive and practical method to screen for hyperglycemia in this patient?

3. A 50-year-old man with type 1 diabetes received a successful kidney transplant 2 years ago. He continues to have severe hypoglycemia and glycemic lability despite optimal insulin therapy. Which transplant option should be considered for this patient?

4. A 45-year-old woman is being evaluated for pancreas transplantation. She asks about potential benefits on diabetic complications. Which statement best describes the effect of pancreas transplantation on diabetic nephropathy?

5. Which risk factors for PTDM are specifically related to transplantation?

6. A patient with type 1 diabetes underwent islet transplantation 3 years ago. She is no longer insulin-independent but maintains C-peptide secretion. What benefits can she expect from this residual graft function?

7. A 40-year-old woman with type 1 diabetes and ESRD is being counseled about transplant options. She wants to understand the comparative benefits of SPK versus kidney transplant alone. What is the primary advantage of SPK transplantation over kidney transplant alone in type 1 diabetes patients with ESRD?

8. A 47-year-old man is undergoing distal pancreatectomy for a benign tumour. He has risk factors for diabetes including obesity and family history. Why might islet autotransplantation be particularly important for this patient?

9. A 35-year-old man with type 1 diabetes has marked glycemic lability and severe hypoglycemia despite optimal medical therapy including insulin pump and continuous glucose monitoring. He has preserved renal function with an eGFR of 85 mL/min. What is a key benefit of islet transplantation even in the absence of complete insulin independence?

10. What is the most common reason for long-term pancreas transplant loss?

11. A 38-year-old woman with chronic painful pancreatitis is scheduled for total pancreatectomy. She does not currently have diabetes. What procedure should be considered to prevent or ameliorate post-pancreatectomy diabetes?

12. A 35-year-old man with type 1 diabetes has marked glycemic lability and severe hypoglycemia despite optimal medical therapy including insulin pump and continuous glucose monitoring. He has preserved renal function with an eGFR of 85 mL/min. Which transplant options may be considered for this patient?

13. Through which route are islets infused during islet allotransplantation?

14. A 45-year-old woman with PTDM is being managed post-liver transplant. Her A1C is 8.2% on metformin alone. She has normal renal function. What small studies have suggested regarding DPP-4 inhibitors in PTDM?

15. A 52-year-old man is 1 month post-kidney transplant. His fasting glucose is 5.8 mmol/L but his post-lunch glucose at 4 pm is 11.2 mmol/L. He has no symptoms of hyperglycemia. How should this finding be interpreted and managed?

16. A 60-year-old man with pre-existing type 2 diabetes undergoes heart transplantation. Post-operatively, his blood glucose levels are significantly elevated. What is the recommended approach for glycemic management in the acute post-transplant setting?

17. What percentage of patients undergoing total pancreatectomy will have meaningful glycemic benefit from islet autotransplantation?

18. What percentage of procedural complications occur with islet transplantation at experienced centres?

19. According to guidelines, when should A1C be measured to screen for PTDM after solid organ transplantation?

20. At what time point post-transplant can A1C ≥6.5% be used to diagnose PTDM in stable recipients?

21. Why is pre-transplant screening for diabetes and CV risk factors recommended?

22. Post-transplant diabetes mellitus (PTDM) was previously known as:

23. What is the 15-year graft survival rate for simultaneous pancreas-kidney transplantation?

24. What is a potential complication specific to islet transplantation procedures?

25. A 55-year-old man developed PTDM 6 months after liver transplantation. He has mild renal impairment (eGFR 55 mL/min) and a BMI of 32 kg/m². He is currently on tacrolimus and low-dose prednisone. Which class of antihyperglycemic agents would be generally preferred as first-line therapy for this patient?

26. A patient is considering islet versus pancreas transplantation. Which statement correctly compares these options?

27. What is a major advantage of islet autotransplantation compared to islet allotransplantation?

28. Which diagnostic test is the LEAST sensitive for detecting PTDM?

29. What is the 1-year graft survival rate for simultaneous pancreas-kidney (SPK) transplantation?

30. What is an advantage of considering PAK or IAK in patients with a functioning kidney transplant?

31. What is a concern when considering SGLT2 inhibitors in immunosuppressed transplant recipients?

32. A patient asks about the risks of pancreas transplantation surgery. Which complications are specifically associated with pancreas transplantation surgery?

33. A patient with PTDM has renal impairment with eGFR of 25 mL/min and a poorly functioning pancreas transplant. Which class of antihyperglycemic agents should be avoided in this patient?

34. Which type of pancreas transplantation has the highest 5-year graft survival rate?

35. What is the median pancreas graft survival after transplantation?

36. What is a characteristic metabolic outcome after successful pancreas transplantation?

37. PTDM is associated with which of the following outcomes?


 

Categories
CDE Diabetes

Study Guide: Diabetes and Transplantation (Chapter 20)

1. Overview & Rationale

Diabetes is a bidirectional issue in transplantation: it is the leading cause of kidney failure requiring transplant, and transplantation (and its associated medications) can cause new-onset diabetes.

  • Kidney Transplant: For people with diabetes and End Stage Renal Disease (ESRD), kidney transplantation provides better long-term outcomes than dialysis.
  • Beta-Cell Replacement: Whole pancreas or islet transplantation can restore endogenous insulin, stabilizing glucose and preventing severe hypoglycemia in Type 1 Diabetes.
  • Post-Transplant Diabetes Mellitus (PTDM): A common complication after solid organ transplant, associated with reduced graft survival and increased mortality.

2. Transplantation Options for Type 1 Diabetes

A. Pancreas Transplantation

This involves major abdominal surgery but offers the highest chance of long-term insulin independence.

  • Simultaneous Pancreas-Kidney (SPK):
    • Indication: Type 1 Diabetes + ESRD.
    • Benefit: Improves kidney graft survival compared to kidney transplant alone. It prolongs insulin independence and patient survival.
    • Success: Median graft survival is ~9 years.
  • Pancreas After Kidney (PAK): For those who already have a functioning kidney transplant.
  • Pancreas Transplant Alone (PTA): Rare; for those with severe metabolic complications but preserved kidney function.

B. Islet Transplantation

A minimally invasive procedure where islets are infused into the liver via the portal vein.

  • Islet Allotransplantation (Donor Islets):
    • Goal: Primarily to prevent severe hypoglycemia and restore hypoglycemia awareness, even if total insulin independence isn’t achieved.
    • Outcome: 5-year insulin independence rates have improved to ~60%.
  • Islet Autotransplantation (Self Islets):
    • Indication: People undergoing total/partial pancreatectomy for benign disease (e.g., chronic pancreatitis).
    • Benefit: Prevents surgical diabetes; does not require immunosuppression because the cells are the patient’s own.

 

3. Comparison: Islet vs. Pancreas Transplant (Table 2)

This comparison is high-yield for the exam.

FeatureIslet
Transplant		Pancreas
Transplant
InvasivenessMinimally invasive (infusion)Major abdominal surgery
Insulin IndependenceVariable; may require multiple infusionsHigh rate; more durable
Primary GoalEliminate severe hypoglycemiaInsulin independence & Renal protection (SPK)
ImmunosuppressionRequired (Life-long)Required (Life-long)
SteroidsGenerally AvoidedMay be used

4. Post-Transplant Diabetes Mellitus (PTDM)

Formerly known as “New Onset Diabetes After Transplantation” (NODAT).

Risk Factors:

  • General: Age, obesity, family history, metabolic syndrome.
  • Transplant-Specific: Hepatitis C, Cytomegalovirus (CMV), Corticosteroids, Calcineurin inhibitors (immunosuppressants).

Screening & Diagnosis:

  • Early Period (0–3 months):
    • Hyperglycemia is common due to high-dose steroids and stress.
    • Screening: Monitor post-lunch (4 pm) capillary blood glucose.
    • A1C: NOT reliable in the first 3 months due to surgical blood loss/transfusions/turnover.
  • Stable Period (>3 months):
    • A1C 6.5% can be used for diagnosis once the patient is stable.
    • OGTT: The standard 2-hour Oral Glucose Tolerance Test is the most sensitive but often impractical. Fasting Plasma Glucose (FPG) is the least sensitive.

Management of PTDM:

  • Insulin: Preferred agent in the acute hospital setting or during high-dose steroid therapy.
  • Metformin: First-line oral agent if renal function is stable.
  • Secretagogues (Sulfonylureas/Meglitinides): AVOID in patients with renal impairment or pancreas transplant dysfunction to preserve beta-cell mass and avoid hypoglycemia.
  • SGLT2 Inhibitors: Use with caution due to infection risk in immunosuppressed patients.

Diabetes CanadaClinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page 5147).

  1. SPK Selection: Individuals with Type 1 diabetes and ESRD should be considered for Simultaneous Pancreas-Kidney (SPK) transplantation [Grade C, Level 3].
  2. Islet Consideration: Islet allotransplantation may be considered for T1D with marked glycemic lability or severe hypoglycemia despite optimal care [Grade C, Level 3].
  3. PTDM Screening:
    • Screen for PTDM with A1C at 3 months, 12 months, and annually [Grade C, Level 3].
    • Use OGTT or post-lunch monitoring in the first 3 months (when A1C is unreliable) [Grade C, Level 3].
  4. PTDM Management:
    • Treat to individualized targets.
    • Avoid insulin secretagogues if renal impairment is present [Grade D, Consensus].
    • Use insulin for metabolic decompensation [Grade D, Consensus].

Reference:

Senior PA, AlMehthel M, Miller A, Paty BW. Diabetes and Transplantation. Canadian Journal of Diabetes. 2018;42:S145-S149. doi:10.1016/j.jcjd.2017.10.017
Categories
CDE Diabetes

Flashcards: Influenza, Pneumococcal, Hepatitis B and Herpes Zoster Vaccinations (Chapter 19 & Updates)

Vaccination is a cornerstone of preventative care for people with diabetes, who face higher risks of infection-related morbidity. These flashcards integrate the foundational knowledge from Chapter 19 with the critical updates from the 2024/2025 Immunization Tool, helping you navigate the shift toward newer conjugate vaccines and expanded protection.

Key Topics Covered:

  • Pneumococcal Update: Memorizing the new standard: a single dose of Pneu-C-21 or Pneu-C-20 for adults, regardless of prior vaccination history with Pneu-C-13 or Pneu-P-23.
  • Herpes Zoster (Shingles): Understanding the recommendation for the Recombinant Zoster Vaccine (RZV) and the required 1-year wait period for those who previously received the live vaccine or had an episode of shingles.
  • Influenza: Reinforcing the need for annual vaccination to reduce hospitalization risk by ~40% and all-cause mortality.
  • Hepatitis B: Identifying adults with diabetes as a high-risk group (due to assisted blood glucose monitoring) requiring catch-up immunization.
  • Emerging Vaccines: Reviewing the individualized recommendations for Respiratory Syncytial Virus (RSV) and updated COVID-19 boosters.
Categories
CDE Diabetes

Practice Exam: Influenza, Pneumococcal, Hepatitis B and Herpes Zoster Vaccinations (Chapter 19 & Updates)

People with diabetes are at a significantly higher risk for morbidity and mortality from vaccine-preventable diseases compared to the general population. The Clinical Practice Guidelines emphasize that vaccination is a critical, yet often overlooked, component of comprehensive diabetes care.

This practice exam tests your ability to apply the 2018 Guidelines and the most recent 2024/2025 Immunization Tool recommendations, covering routine schedules and specific indications for high-risk adults.

Key Concepts Covered in This Exam:

  • Influenza: Understanding the recommendation for annual vaccination to reduce hospitalization rates (by approx. 40%) and death during flu season.
  • Pneumococcal Updates: Mastering the updated protocols which now recommend one dose of Pneu-C-21 or Pneu-C-20 for adults, regardless of their previous vaccination status with Pneu-C-13 or Pneu-P-23.
  • Hepatitis B: Recognizing that adults with diabetes are at higher risk of Hepatitis B infection (e.g., from assisted blood glucose monitoring) and should be immunized if not vaccinated in childhood.
  • Herpes Zoster (Shingles): Identifying the recommendation for the Recombinant Zoster Vaccine (RZV) for adults 50 years, including those who have previously received the live vaccine.
  • Emerging Vaccines: Reviewing new guidance for COVID-19 boosters and the individualized recommendation for Respiratory Syncytial Virus (RSV) vaccination in high-risk populations, including those with diabetes.
Please go to Practice Exam: Influenza, Pneumococcal, Hepatitis B and Herpes Zoster Vaccinations (Chapter 19 & Updates) to view this quiz
Categories
CDE Diabetes

Study Guide: Immunization in Diabetes (Updated 2025)

1. Overview & Principles

People with diabetes are at higher risk for complications from vaccine-preventable diseases. The new 2025 guidance emphasizes a broader range of vaccines and simplified protocols for pneumococcal protection.

  • Advocacy: Clinicians should discuss ALL age-appropriate vaccines regardless of public/private coverage.
  • Timing: Routine childhood immunizations should be up to date (refer to provincial schedules).
  • Timing: Routine childhood immunizations should be up to date (refer to provincial schedules).

2. Routine & Annual Vaccinations

These are “Ongoing Immunizations” recommended for adults with diabetes.

  • COVID-19:
    • Frequency: Annual.
    • High-Risk: Some high-risk individuals may require 2 doses/year.
    • Timing: Minimum 3 months from the last dose or 3 months post-infection.
  • Influenza (Flu Shot):
    • Frequency: Annual.
    • Target: All adults with diabetes.
  • Tetanus-Diphtheria-Pertussis (Tdap):
    • Frequency: Booster every 10 years.

3. One-Time / Series Vaccinations (Major Updates)

The protocols for Pneumococcal and Shingles have been significantly updated from the 2018 guidelines.

A. Invasive Pneumococcal Disease

  • New Recommendation: One dose of Pneu-C-21 OR Pneu-C-20.
  • History: This single dose is recommended regardless of previous vaccination status with Pneu-C-13 (Prevnar-13) or Pneu-P-23 (Pneumovax-23).
  • Age: Recommended for adults age 18+.

B. Herpes Zoster (Shingles)

  • Vaccine Type: Recombinant Zoster Vaccine (RZV) is recommended.
  • Age: Recommended for adults age 50 years.
  • Previous History:
    • If the patient had a previous episode of Shingles: Wait at least 1 year before vaccinating.
    • If the patient received the live vaccine (LZV) previously: Wait at least 1 year before vaccinating with RZV.

C. Respiratory Syncytial Virus (RSV)

  • Strategy: Individualized assessment.
  • Risk Factors: High-risk populations include diabetes, chronic kidney disease (CKD), and obesity.
  • Age: The tool highlights consideration starting at age 60. (Note: Recent NACI guidance also discusses ages 50-59 ).

D. Hepatitis B

  • Indication: Recommended if not vaccinated in childhood or if medical conditions change.
  • Specific Risk: Chronic Kidney Disease (CKD) with or without dialysis.
  • Vaccine: Most people should be immunized with the combined Hepatitis A + B vaccine.

4. Additional Lifetime Recommendations

These are not specific only to diabetes but are part of comprehensive care.

  • Human Papillomavirus (HPV): Recommended if not previously vaccinated with a complete series (up to age ~44 in chart).
  • Meningococcal-ACYW: Booster at 12–24 years old (even if vaccinated as an infant).
  • Measles-Mumps-Rubella (MMR): Adults born in or after 1970 should receive one dose.

References:

Husein N, Chetty A. Influenza, Pneumococcal, Hepatitis B and Herpes Zoster Vaccinations. Canadian Journal of Diabetes. 2018;42:S142-S144. doi:10.1016/j.jcjd.2017.10.016
 
Diabetes Canada. Immunizations Recommended for Adults Living with Diabetes. Accessed August 23, 2025. https://guidelines.diabetes.ca/getmedia/5365a51d-a34b-4176-bb1f-beed55239ebb/Immunization-Tool_Ver_3.pdf
Categories
CDE Diabetes

Flashcards: Diabetes and Mental Health (Chapter 18 Update)

The 2023 Guidelines emphasize that mental health is not secondary to physical health in diabetes care; the two have a bidirectional relationship that significantly impacts outcomes. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the diagnostic distinctions, screening tools, and management strategies for the psychosocial challenges faced by people living with diabetes.

Key Topics Covered:

  • Diabetes Distress vs. Depression: Understanding the difference between the emotional burden of diabetes management (distress) and clinical depression, and why this distinction matters for treatment.

  • Screening Protocols: Memorizing the recommendation to routinely screen for diabetes distress, anxiety, and depressive symptoms using validated tools.

  • Eating Disorders: Identifying “diabulimia” (insulin omission for weight loss) in Type 1 diabetes and recognizing Binge Eating Disorder in Type 2 diabetes.

  • Serious Mental Illness: Reviewing the metabolic risks associated with schizophrenia and bipolar disorder, specifically the impact of antipsychotic medications on weight and insulin sensitivity.

  • Interventions: Recalling evidence-based psychosocial interventions like Cognitive Behavioural Therapy (CBT) and their role in improving quality of life.

Categories
CDE Diabetes

Practice Exam: Diabetes and Mental Health (Chapter 18 Update)

Mental health is integral to diabetes care. The 2023 Guidelines highlight the bidirectional relationship between diabetes and psychiatric disorders, emphasizing that psychological well-being is a critical predictor of successful self-management and metabolic outcomes.

This practice exam tests your ability to identify, screen for, and manage the psychosocial challenges commonly faced by individuals living with diabetes, ranging from diagnosis-related distress to severe mental illness.

Key Concepts Covered in This Exam:

  • Diabetes Distress vs. Depression: Distinguishing between the emotional burden of living with diabetes (distress) and Major Depressive Disorder, and knowing when to refer for specialized care.

  • Screening Protocols: Understanding the recommendation to routinely screen for diabetes distress, anxiety disorders, and depressive symptoms using validated tools.

  • Eating Disorders: Recognizing “diabulimia” (insulin omission for weight loss) in Type 1 diabetes and Binge Eating Disorder in Type 2 diabetes as critical barriers to glycemic control.

  • Serious Mental Illness: Managing the metabolic risks associated with schizophrenia and bipolar disorder, including the impact of antipsychotic medications on weight and insulin resistance.

  • Psychosocial Interventions: Identifying evidence-based interventions such as Cognitive Behavioural Therapy (CBT) and motivational interviewing to improve adherence and quality of life.

Please go to Practice Exam: Diabetes and Mental Health (Chapter 18 Update) to view this quiz

Categories
CDE Diabetes

Study Guide: Diabetes and Mental Health (2023 Update)

1. Overview

The relationship between diabetes and mental health is bidirectional. Having diabetes increases the risk of psychiatric disorders, and psychiatric disorders increase the risk of developing diabetes (and complicating its management).

  • Prevalence: Mental health disorders are more common in people with diabetes than the general population.

  • Impact: Co-occurring mental health issues lead to:

    • Decreased self-care participation.

    • Reduced quality of life.

    • Increased risk of diabetes complications.

    • Increased healthcare costs.

    • Earlier all-cause mortality (specifically for depression).

2. Screening Recommendations (The "30-Second" Rule)

The guidelines emphasize regular screening using validated tools. You don’t need to be a psychiatrist to screen; it is a core CDE competency.

ConditionFrequencyScreening
Tool
Examples		Notes
Diabetes DistressRoutine / Regular

DDS
 (Diabetes Distress Scale)


PAID
 (Problem Areas in Diabetes)

Distress is distinct from depression. It relates specifically to the burden of diabetes management.
DepressionRoutine / Regular

PHQ-9
 (Patient Health Questionnaire)


HADS
(Hospital Anxiety and Depression Scale)

Depression affects ~30% of people with diabetes (10% major depression).
Anxiety DisordersRoutine / RegularGAD-7
 (Generalized Anxiety Disorder-7)		Generalized Anxiety Disorder affects ~14% of people with diabetes.
Eating DisordersAs clinically indicatedDEPS-R
 (Diabetes Eating Problem Survey-Revised)		Especially “Diabulimia” (insulin restriction to lose weight) in T1D.

 

3. Key Conditions & Associations

A. Diabetes Distress

  • Definition: An emotional response to the burden of living with and managing diabetes (e.g., “burnout,” feeling overwhelmed). It is not a psychiatric disorder but can lead to one if untreated.

  • Management: Education, support, and validating feelings often help. It does not necessarily require medication; it requires diabetes-specific support.

B. Depression

  • Link: Bi-directional.

  • Treatment:

    • Psychotherapy (CBT is gold standard).

    • Pharmacotherapy (SSRIs/SNRIs). Note: Treatment improves mood but does not consistently improve A1C unless self-care behaviors also change.

C. Schizophrenia & Bipolar Disorder

  • Risk: People with these conditions have a higher risk of developing Type 2 diabetes.

  • Medication Impact: Second-generation (atypical) antipsychotics (e.g., olanzapine, clozapine, quetiapine) are associated with significant metabolic side effects (weight gain, dyslipidemia, hyperglycemia).

  • Recommendation: Mandatory metabolic monitoring (weight, waist circumference, BP, FPG/A1C, lipids) for anyone on atypical antipsychotics.

D. Eating Disorders

  • Insulin Omission: In Type 1 diabetes, restricting insulin to cause glycosuria and weight loss is a dangerous purging behavior (often called “Diabulimia”).

  • Screening: Look for unexplained A1C elevation, recurrent DKA, or weight loss despite reported good intake.

4. Psychosocial Treatment Approaches

The guidelines recommend integrating psychosocial care into routine diabetes practice.

  • Motivational Interviewing (MI): A person-centered approach to strengthen motivation for change.

  • Cognitive Behavioral Therapy (CBT): Effective for depression and anxiety in diabetes.

  • Coping Skills Training: Helps patients manage stress and the mental load of diabetes.

  • Family Therapy: Particularly useful for children/adolescents to address family conflict regarding management.

5. Diabetes Canada Clinical Practice Guidelines Recommendations

  • Screening: All individuals with diabetes should be regularly screened for diabetes distress and symptoms of common psychiatric disorders (depression, anxiety) [Grade D, Consensus].

  • Psychosocial Interventions: Incorporate interventions like CBT, motivational interviewing, and coping skills training into care to improve outcomes [Grade B, Level 2].

  • Severe Mental Illness: Individuals with severe mental illness (schizophrenia, bipolar) require frequent screening for diabetes and metabolic risk factors, especially if prescribed atypical antipsychotics [Grade D, Consensus].

  • Youth: Adolescents with Type 1 diabetes should be screened for eating disorders (insulin omission) when there is unexplained hyperglycemia or weight loss [Grade D, Consensus].

Reference:

Robinson DJ, Hanson K, Jain AB, et al. Diabetes and Mental Health – 2023. Canadian Journal of Diabetes. 2023;47(4):308-344. doi:10.1016/j.jcjd.2023.04.009